Investigating the impact of botulinum toxin type a on the migration of normal human dermal fibroblasts: An in vitro wound healing assay.
botulinum toxin type a
fibroblast migration
in vitro assay
scar prevention
wound healing
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
22
03
2024
accepted:
10
05
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
20
6
2024
Statut:
aheadofprint
Résumé
Botulinum toxin A (BoNT-A) is widely utilized in the management of hypertrophic and keloid scars. One proposed mechanism for scar prevention involves the inhibition of fibroblast migration in scars by BoNT-A. However, the data regarding the effect of BoNT-A on the migration of normal human dermal fibroblasts (NHDF) is limited. The aim of this study was to investigate the inhibitory effect of different types and dilutions of BoNT-A on the migration of NHDF. In vitro scratch wound assay, NHDF cells were cultured, incubated, and subjected to scratching using a sterile tip. Subsequently, the scratched NHDF monolayer was treated with different types of BoNT-A, including onabotulinumtoxinA (ONA), incobotulinumtoxinA (INCO), prabotulinumtoxinA (PRABO), or letibotulinumtoxinA (LETI), at varying concentrations of 10, 20, 25, 40, 50, and 100 units/milliliter (U/mL). Additionally, abobotulinumtoxinA (ABO) was administered at concentrations of 33, 50, 66, 71, 100, 150, 300, and 500 U/mL. Normal saline solution (NSS) served as a negative control. The extent of NHDF migration was evaluated by comparing each dilution of BoNT-A with the controls using high-content imaging at the 48-h time point. Furthermore, the viability of the of NHDF was assessed. The concentrations of 25, 40, and 50 U/mL of ONA (p < 0.001) and 25 U/mL of LETI (p < 0.05) demonstrated significantly inhibited NHDF migration in comparison to the control group. Conversely, all dilutions of PRABO, INCO, and ABO exhibited comparable NHDF migration to that of the control group. Regarding NHDF viability, no significant decrease was observed across any of the BoNT-A types and dilutions. Different types and dilutions of BoNT-A demonstrated variable inhibitory effects on NHDF migration in vitro. The selection of BoNT-A formulation may significantly impact the clinical outcome of scar prevention related to fibroblast migration.
Sections du résumé
BACKGROUND
BACKGROUND
Botulinum toxin A (BoNT-A) is widely utilized in the management of hypertrophic and keloid scars. One proposed mechanism for scar prevention involves the inhibition of fibroblast migration in scars by BoNT-A. However, the data regarding the effect of BoNT-A on the migration of normal human dermal fibroblasts (NHDF) is limited.
OBJECTIVES
OBJECTIVE
The aim of this study was to investigate the inhibitory effect of different types and dilutions of BoNT-A on the migration of NHDF.
METHODS
METHODS
In vitro scratch wound assay, NHDF cells were cultured, incubated, and subjected to scratching using a sterile tip. Subsequently, the scratched NHDF monolayer was treated with different types of BoNT-A, including onabotulinumtoxinA (ONA), incobotulinumtoxinA (INCO), prabotulinumtoxinA (PRABO), or letibotulinumtoxinA (LETI), at varying concentrations of 10, 20, 25, 40, 50, and 100 units/milliliter (U/mL). Additionally, abobotulinumtoxinA (ABO) was administered at concentrations of 33, 50, 66, 71, 100, 150, 300, and 500 U/mL. Normal saline solution (NSS) served as a negative control. The extent of NHDF migration was evaluated by comparing each dilution of BoNT-A with the controls using high-content imaging at the 48-h time point. Furthermore, the viability of the of NHDF was assessed.
RESULTS
RESULTS
The concentrations of 25, 40, and 50 U/mL of ONA (p < 0.001) and 25 U/mL of LETI (p < 0.05) demonstrated significantly inhibited NHDF migration in comparison to the control group. Conversely, all dilutions of PRABO, INCO, and ABO exhibited comparable NHDF migration to that of the control group. Regarding NHDF viability, no significant decrease was observed across any of the BoNT-A types and dilutions.
CONCLUSION
CONCLUSIONS
Different types and dilutions of BoNT-A demonstrated variable inhibitory effects on NHDF migration in vitro. The selection of BoNT-A formulation may significantly impact the clinical outcome of scar prevention related to fibroblast migration.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Matak I, Lackovic Z. Botulinum neurotoxin type a: actions beyond SNAP‐25? Toxicology. 2015;335:79‐84.
Jagdeo J, Carruthers A, Smith KC. New frontiers and clinical applications for botulinum neuromodulators. Dermatologic Surg. 2015;41(Suppl 1):S17‐S18.
Scott AB, Kennedy RA, Stubbs HA. Botulinum a toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103(3):347‐350.
Wheeler T. Sweat and tears: treating the patient with primary hyperhidrosis. Br J Nurs. 2012;21(7):408‐412.
Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR. Botulinum toxin type a for the treatment and prevention of hypertrophic scars and keloids: updated review. J Cosmet Dermatol. 2019;18(1):10‐15.
Yang W, Li G. The safety and efficacy of botulinum toxin type a injection for postoperative scar prevention: a systematic review and meta‐analysis. J Cosmet Dermatol. 2020;19(4):799‐808.
Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to botulinum toxin a: a comprehensive literature review. Dermatologic Surg. 2018;44(2):149‐157.
Park GS, An MK, Yoon JH, et al. Botulinum toxin type a suppresses pro‐fibrotic effects via the JNK signaling pathway in hypertrophic scar fibroblasts. Arch Dermatol Res. 2019;311(10):807‐814.
Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatologic Surg. 2017;43(Suppl 1):S3‐S18.
Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the pathophysiology of hypertrophic scars and keloids: how do they differ? Adv Skin Wound Care. 2018;31(1):582‐595.
Wagner JA. Therapy of pathological scars. J Dtsch Dermatol Ges. 2013;11(12):1139‐1157.
Hou Z, Fan F, Liu P. BTXA regulates the epithelial‐mesenchymal transition and autophagy of keloid fibroblasts via modulating miR‐1587/miR‐2392 targeted ZEB2. Biosci Rep. 2019;39(10):BSR20190679.
Grando SA, Zachary CB. The non‐neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond. Br J Dermatol. 2018;178(5):1011‐1019.
Kim S, Ahn M, Piao Y, et al. Effect of botulinum toxin type a on TGF‐beta/Smad pathway signaling: implications for silicone‐induced capsule formation. Plast Reconstr Surg. 2016;138(5):821e‐829e.
Zhibo X, Miaobo Z. Botulinum toxin type a affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg. 2008;61(9):1128‐1129.
Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesth Plast Surg. 2011;35(5):802‐807.
Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK, Kim HW. Effect of botulinum toxin type a on a rat surgical wound model. Clin Exp Otorhinolaryngol. 2009;2(1):20‐27.
Liu DQ, Li XJ, Weng XJ. Effect of BTXA on inhibiting hypertrophic scar formation in a rabbit ear model. Aesth Plast Surg. 2017;41(3):721‐728.
Lee SD, Yi MH, Kim DW, Lee Y, Choi Y, Oh SH. The effect of botulinum neurotoxin type a on capsule formation around silicone implants: the in vivo and in vitro study. Int Wound J. 2016;13(1):65‐71.
Oh SH, Lee Y, Seo YJ, et al. The potential effect of botulinum toxin type a on human dermal fibroblasts: an in vitro study. Dermatologic Surg. 2012;38(10):1689‐1694.
Haubner F, Ohmann E, Muller‐Vogt U, Kummer P, Strutz J, Gassner HG. Effects of botulinum toxin a on cytokine synthesis in a cell culture model of cutaneous scarring. Arch Facial Plast Surg. 2012;14(2):122‐126.
Zhang DZ, Liu XY, Xiao WL, Xu YX. Botulinum toxin type a and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta‐analysis of randomized controlled trials. PLoS One. 2016;11(3):e0151627.